AstraZeneca【AZN】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

54.17

買値

売値

出来高

0.00 日の範囲 0.00

0.00 52 週間の範囲 0.00

時価総額

83.993B

前日終値

54.17

始値

時刻

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

発行済株式数

1,550,546,000

配当利回り

PER

24.69

1 株当たり利益 (EPS)

4.54

歳入

54.07B

純利益

7.04B

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from intern... A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its revenue. 詳細を表示

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.astrazeneca.com

本社

Cambridge, Gbr

設立

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

Pre-exposure prophylaxis (prevention) trial reduced risk of symptomatic COVID-19, with no severe disease or COVID-19-related deaths in EVUSHELD...

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

Analysis of Phase III CHAMPION-MG trial open-label extension adds to growing body of safety and efficacy data...

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

Partnership contributes to the AZ Forest global initiative to plant and maintain 50 million trees worldwide by the end of 2025 AstraZeneca has...

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

First in vivo data from Washington University show EVUSHELD reduces viral burden of all tested Omicron subvariants in the lungs New preclinical...

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

First HER2-low metastatic breast cancer Phase III results for AstraZeneca and Daiichi Sankyo’s ENHERTU offer potential to redefine how the...

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Combination was well tolerated and allowed patients to maintain their quality of life vs. patients treated with abiraterone alone PROpel Phase...

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of...

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

A single priming dose of tremelimumab plus IMFINZI every four weeks reduced risk of death by 22% in HIMALAYA Phase III trial Combination also...

IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer

TOPAZ-1 is the first Phase III trial to show improved survival with an immunotherapy combination in this setting Combination did not increase...

CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

Based on ground-breaking DESTINY-Breast03 results showing AstraZeneca and Daiichi Sankyo’s ENHERTU reduced the risk of disease progression or...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

AZN - Frequently Asked Questions (FAQ)

What is the current AstraZeneca share price?

The current share price of AstraZeneca is US$ 54.17

How many AstraZeneca shares are in issue?

AstraZeneca has 1,550,546,000 shares in issue

What is the market cap of AstraZeneca?

The market capitalisation of AstraZeneca is USD 83.99B

What is the 1 year trading range for AstraZeneca share price?

AstraZeneca has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of AstraZeneca?

The price to earnings ratio of AstraZeneca is 24.69

What is the cash to sales ratio of AstraZeneca?

The cash to sales ratio of AstraZeneca is 3.21

What is the reporting currency for AstraZeneca?

AstraZeneca reports financial results in USD

What is the latest annual turnover for AstraZeneca?

The latest annual turnover of AstraZeneca is USD 54.07B

What is the latest annual profit for AstraZeneca?

The latest annual profit of AstraZeneca is USD 7.04B

What is the registered address of AstraZeneca?

The registered address for AstraZeneca is 1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE, CB2 0AA

What is the AstraZeneca website address?

The website address for AstraZeneca is www.astrazeneca.com

Which industry sector does AstraZeneca operate in?

AstraZeneca operates in the PHARMACEUTICAL PREPARATIONS sector

銘柄コード	株価	出来高
VPGVishay Precision Group Inc	US$ 28.30 (20.37%)	1.23M
XYFX Financial	US$ 16.17 (13.87%)	540.7k
BKKTBakkt Holdings Inc	US$ 10.31 (13.55%)	426.35k
SMCSummit Midstream Corporation	US$ 36.78 (10.62%)	169.04k
AMTMAmentum Holdings Inc	US$ 19.71 (10.30%)	5.9M
NMAXNewsmax Inc	US$ 52.52 (-77.46%)	10.32M
BODIBeachbody Company Inc	US$ 6.245 (-13.86%)	27.01k
DTCSolo Brands Inc	US$ 0.1571 (-11.24%)	1.23M
GWHESS Tech Inc	US$ 2.586 (-9.26%)	110.12k
BBBlackBerry Limited	US$ 3.39 (-9.12%)	33.86M
FFord Motor Company	US$ 10.14 (2.01%)	136.9M
RIGTransocean Ltd	US$ 3.153 (-5.03%)	62.32M
NUNu Holdings Ltd	US$ 10.585 (1.49%)	55.95M
NIONIO Inc	US$ 3.80 (-1.81%)	46.01M
BBAIBigBear ai Holdings Inc	US$ 3.125 (5.93%)	42.49M

銘柄コード

株価

出来高

FFord Motor Company

US$ 10.14

(2.01%)

136.9M

RIGTransocean Ltd

US$ 3.153

(-5.03%)

62.32M

NUNu Holdings Ltd

US$ 10.585

(1.49%)

55.95M

NIONIO Inc

US$ 3.80

(-1.81%)

46.01M

BBAIBigBear ai Holdings Inc

US$ 3.125

(5.93%)

42.49M

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

AstraZeneca PLC (AZN)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

AstraZeneca PLC について

AZN 最新ニュース

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer

CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

AZN - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

市場データ

ニュース

投資ツール

市場

発見

Hot Features

Follow Feed

ライブオプションフロー

モニター

AstraZeneca PLC (AZN) 銘柄情報

AstraZeneca PLC (AZN)

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

主要統計と詳細

AstraZeneca PLC について

AZN 最新ニュース

EVUSHELD™ significantly protected against symptomatic COVID-19 for at least six months in PROVENT Phase III trial in high-risk populations

ULTOMIRIS® (ravulizumab-cwvz) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks

AstraZeneca Announces New Partnership with The National Fish and Wildlife Foundation to Plant One Million Trees

EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies

ENHERTU® (fam-trastuzumab deruxtecan-nxki) Significantly Improved Both Progression-Free and Overall Survival in DESTINY-Breast04 Trial in Patients with HER2-Low Metastatic Breast Cancer

LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer

Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis

IMFINZI® (durvalumab) Plus Tremelimumab Demonstrated Unprecedented Survival in 1st-line Unresectable Liver Cancer With 31% of Patients Alive at Three Years

IMFINZI® (durvalumab) Plus Chemotherapy Reduced Risk of Death by 20% in 1st-Line Advanced Biliary Tract Cancer

CORRECTING and REPLACING ENHERTU® granted Priority Review in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen

AZN - Frequently Asked Questions (FAQ)

ムーバー

議論

最近閲覧した銘柄

会社情報

ビジネス

人気

アプリを入手

広告を削除する

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR